Sign in to fuzzto save your conversations, follow your research and come back anytime.
Divis Laboratories
SectorHealthcare
Divi's Laboratories Ltd is a leading pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals. The company operates globally with a presence in over 100 countries and has six manufacturing facilities. It offers both generic and custom synthesis services for pharmaceutical companies, supporting product development from clinical trials to market launch. Divi's Laboratories has two main subsidiaries: Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG, which focus on marketing nutraceutical products. The company has research centers in Hyderabad and at its manufacturing sites, with a focus on custom synthesis and contract research. Divi's Laboratories has expanded its operations over the years, establishing multiple manufacturing units, including special economic zones (SEZs), and has undergone various regulatory inspections and certifications. The company continues to invest in capacity expansion and infrastructure upgrades to meet growing market demands.
In the news
Citi Maintains Buy on Divi's Labs with Rs 11,700 Target
Divis Laboratories trades at ₹8367, Motilal Oswal maintains ₹7720 target
Divi's Q1 profit surges 66% to ₹902 crore, shares hit 52-week high
Divi's Labs shares surge 2.7% on Macquarie's ₹10,200 target
Dixon Technologies Surges on Vivo JV Approval and ₹62,500 Cr Scheme
Divi's Lab Confirms Golden Cross Amid Mixed Performance
Divi's Labs Q4 FY26: Profit Beats Estimates Despite Margin Slip
Divi's Laboratories Q4 profit jumps 13.44% to ₹751 cr, beats estimates
Company insights, generated from the most recent coverage.
Q1 FY27 PAT surged 65.5% YoY to ₹902 Cr while revenue grew 24.3% to ₹3,144 Cr, demonstrating strong operating leverage.
Custom synthesis contributes 60% of revenue with 90% export dependence (75% to Europe/North America), providing high-margin sticky business model.
Two VPs (Procurement and Projects) retired simultaneously in July 2026; routine exits but potential near-term sentiment overhang.